---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027085"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T20:58:02.722207+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites

## Summary
- Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.
- Agreement covered Phase 1b trial of LB-100 combined with Carboplatin/Etoposide/Atezolizumab for extensive-stage small cell lung cancer.
- Company plans to explore alternative clinical trial sites to continue the study.

## SEC filing metadata
- accession: 0001493152-24-027085
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/0001493152-24-027085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027085
- JSON: https://secwatch.observer/filing/0001493152-24-027085.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.